Massive investments are flooding into the anti-aging biotechnology sector as researchers explore ways to slow or reverse the biological processes of aging. While the potential benefits—such as extending healthy lifespans—are promising, scientists warn that the long-term risks of interfering with aging remain poorly understood. Ethical concerns and unintended consequences could arise as companies race to develop treatments targeting fundamental biological mechanisms. The rapid pace of innovation raises questions about whether society is prepared for the scientific and societal implications of such breakthroughs.
Billions are pouring into anti-ageing biotech, but manipulating ageing has risks we are only beginning to understand.
